Following the data and subsequent validation obtained in lung cancer, breast cancer, and gastric cancer, as well as in melanoma, the molecular profile of the PD-1/PD-L1 immune checkpoint in CTCs could potentially be used as a standalone prognostic indicator for immunotherapy [96,97,98,99,100]. The gene discussed is PDCD1; the disease is melanoma.